F
Fabio Cappuccini
Researcher at University of California, Irvine
Publications - 42
Citations - 1120
Fabio Cappuccini is an academic researcher from University of California, Irvine. The author has contributed to research in topics: Ovarian cancer & Tumor necrosis factor alpha. The author has an hindex of 18, co-authored 37 publications receiving 1054 citations. Previous affiliations of Fabio Cappuccini include California State University, Long Beach & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Malignant germ cell tumors of the ovary.
Krishnansu S. Tewari,Fabio Cappuccini,Philip J. DiSaia,Michael L. Berman,Alberto Manetta,Matthew F. Kohler +5 more
TL;DR: It is confirmed that platinum-based adjuvant treatments allow most women with ovarian germ cell malignancies to have conservative surgery without compromising survival.
Journal ArticleDOI
Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.
Tetsuya Gatanaga,Chenduen Hwang,William Kohr,Fabio Cappuccini,Joseph A. Lucci,Edward W. B. Jeffes,Rigdon Lentz,John M. Tomich,Robert S. Yamamoto,Gale A. Granger +9 more
TL;DR: Serum ultrafiltrates from human patients with different types of cancer contain a blocking factor (BF) that inhibits the cytolytic activity of human tumor necrosis factor alpha (TNF-alpha) in vitro and may have an important role in regulation and control of TNF- alpha and lymphotoxin activity in cancer patients.
Journal ArticleDOI
Obstetric emergencies precipitated by malignant brain tumors.
Krishnansu S. Tewari,Fabio Cappuccini,Tamerou Asrat,Bruce L. Flamm,Sidney E. Carpenter,Philip J. DiSaia,Edward J. Quilligan +6 more
TL;DR: To minimize temporal lobe or cerebellar herniation in neurologically unstable patients, a consideration should be made for cesarean delivery with the patient under general anesthesia, followed by immediate neurosurgical decompression.
Journal ArticleDOI
Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy.
TL;DR: In multivariate analysis, platinum-sensitive disease, extreme drug resistance-guided therapy and early stage of disease were independent predictors for improved survival.
Journal ArticleDOI
Advanced-stage small cell carcinoma of the ovary in pregnancy: long-term survival after surgical debulking and multiagent chemotherapy.
Krishnansu S. Tewari,Cheryl A. Brewer,Fabio Cappuccini,Cynthia Macri,Lowell W. Rogers,Michael L. Berman +5 more
TL;DR: This patient had a stage IIIc tumor diagnosed during pregnancy and is alive and without evidence of disease 5(1/2) years after diagnosis, the longest disease-free survival achieved in an advanced-stage small cell carcinoma of the ovary.